Ashley Y. Gao

Ashley Y. Gao

Auto-generated profile, based on publicly available information

Ashley Y. Gao

Mayo Clinic, Department of Ophthalmology, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2022 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
PDF file
AGAshley Y. Gao
Ashley Y. Gao
PLPatrick A. Link
Patrick A. Link
SBSophie J. Bakri
Sophie J. Bakri
AHAndrew J. Haak
Andrew J. Haak
Retinal pigmented epithelial (RPE) cells play an important role in retinal fibrotic diseases such as proliferative vitreoretinopathy (PVR). The purpose of this study was to elucidate the involvement of dopamine receptor signaling in regulating the fibrotic activation of RPE cells. Dopamine receptor expression, the effect of dopamine on fibrotic activity, and dopamine production were measured in the human RPE cell line ARPE-19. The fibrotic activation of RPE cells was evaluated in response to treatments with selective dopamine receptor agonists and antagonists by measuring gene expression, migration, proliferation, and fibronectin deposition. DRD2 and DRD5 are the dominant dopaminergic receptors expressed in ARPE-19 cells and TGF-β stimulation enhances the autocrine release of dopamine, which we show further exasperates fibrotic activation. Finally, treatment with D2 dopamine receptor antagonists or D5 dopamine receptor agonists inhibits profibrotic gene expression, migration, proliferation, and fibronectin deposition and thus may serve as effective mechanisms for treating retinal fibrosis including PVR.

1 December 2022 in American Journal of Physiology-Lung Cellular and Molecular Physiology
Verified
Journal Article
Closed access
PDF file
AGAshley Y. Gao
Ashley Y. Gao
AEAna M. Diaz Espinosa
Ana M. Diaz Espinosa
FGFiorenza Gianì
Fiorenza Gianì
TPTho X. Pham
Tho X. Pham
CCChase M. Carver
Chase M. Carver
AHAndrew J. Haak
Andrew J. Haak
Cellular senescence is emerging as a driver of idiopathic pulmonary fibrosis (IPF), a progressive and fatal disease with limited effective therapies. The senescence-associated secretory phenotype (SASP), involving the release of inflammatory cytokines and profibrotic growth factors by senescent cells, is thought to be a product of multiple cell types in IPF, including lung fibroblasts. NF-κB is a master regulator of the SASP, and its activity depends on the phosphorylation of p65/RelA. The purpose of this study was to assess the role of Pim-1 kinase as a driver of NF-κB-induced production of inflammatory cytokines from low-passage IPF fibroblast cultures displaying markers of senescence. Our results demonstrate that Pim-1 kinase phosphorylates p65/RelA, activating NF-κB activity and enhancing IL-6 production, which in turn amplifies the expression of PIM1, generating a positive feedback loop. In addition, targeting Pim-1 kinase with a small molecule inhibitor dramatically inhibited the expression of a broad array of cytokines and chemokines in IPF-derived fibroblasts. Furthermore, we provide evidence that Pim-1 overexpression in low-passage human lung fibroblasts is sufficient to drive premature senescence, in vitro. These findings highlight the therapeutic potential of targeting Pim-1 kinase to reprogram the secretome of senescent fibroblasts and halt IPF progression.

1 October 2024 in Journal of Ocular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
AGAshley Y. Gao
Ashley Y. Gao
MWMadison G. Whaley
Madison G. Whaley
NSNamita Saraf
Namita Saraf
SBSophie J. Bakri
Sophie J. Bakri
AHAndrew J. Haak
Andrew J. Haak
Purpose: To evaluate the potency and efficacy of a library of dopamine receptor D2 (D2R) antagonists in the mitigation of fibrotic activation in retinal pigment epithelial (RPE) cells. Methods: ARPE-19 cells were cultured and treated with methotrexate or 27 district D2R antagonists using a fibronectin deposition assay. The most potent compounds were then further assessed in assays measuring cellular proliferation, cellular migration, and profibrotic gene expression. Results: The previously established antifibrotic D2R antagonist loxapine exerted a robust and dose-dependent inhibition of fibronectin deposition, whereas methotrexate exerted minimal inhibition. The most potent D2R antagonist identified, fluphenazine, effectively blocked in vitro models of fibrosis at 300–1,000 nM concentrations. Conclusions: Here we found multiple FDA-approved D2R antagonists that potently block RPE cell fibrogenesis. These findings further support the potential of D2R antagonism as a potential therapeutic for retinal fibrotic disease.

15 May 2024 in Visual Journal of Emergency Medicine
Verified
Journal Article
Closed access
AGAshley Y. Gao
Ashley Y. Gao
ANAdam J. Neuhouser
Adam J. Neuhouser
AKAlisha Kamboj
Alisha Kamboj

1 May 2023
Verified
Conference Paper
Closed access
PLP. Link
P. Link
JMJ. Meridew
J. Meridew
NCN. Caporarello
N. Caporarello
AGA.Y. Gao
A.Y. Gao
VPV. Peters
V. Peters
DTD.J. Tschumperlin
D.J. Tschumperlin